MedTrace Logo

Tonabersat in the Prophylaxis of Migraine With Aura

NCT00332007 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2009-08-31

No results posted yet for this study

Summary

Overall trial objectives:

1. Can treatment with tonabersat reduce the number of days with aura and/or migraine headache in patients with migraine with aura
2. How well tolerated is treatment with tonabersat

The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of aura and migraine headache and so be effective as prophylactic treatment

Conditions

  • Migraine With Aura

Interventions

DRUG

Tonabersat

two tablets once daily

DRUG

Placebo

two tablets once daily

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Minster Research Ltd

    lead INDUSTRY

Principal Investigators

  • Jes Olesen, MD · University of Copenhagen, Department of Neurology, Glostrup Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332007 on ClinicalTrials.gov